Another oncology jv example this morning.
Repare Therapeutics (NASDAQ: RPTX), that is
still in preclinicals (Pipeline), signed a jv with Roche. They are into rare genetic tumors.
IPOed in 2020 20$US (
833MM$US).
High was 40$US (
1.6B$US).
Its recent low was 9$US (
$370MM$US) this week.
Now up +40% (12.33$US so
514MM$US) today on that jv deal with Roche.
June 2, 2022 -
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) Repare will receive $125 million up front from Roche. It also could receive up to $1.2 billion in contingent milestone payments if camonsertib hits certain clinical, regulatory, commercial, and sales goals. Up to $55 million of that total could be received in the near term. If camonsertib wins regulatory approval, Repare stands to receive royalties on net sales in the high-single-digit to high-teens percentages.
As icing on the cake, the small drugmaker has an option to split U.S. development, commercialization, and profit sharing on a 50-50 basis with Roche. This could boost Repare's revenue in the future if camonsertib earns approval from the Food and Drug Administration.
Repare had been snobbed for a while, despite a highly regarded article in Nature recently.
April 20, 2022 - Nature journal -
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification